EasySep™ Mouse B Cell Isolation Kit

15-Minute cell isolation kit using immunomagnetic negative selection

New format, same high quality! You may notice that your kit contents and packaging look slightly different from previous orders. We are currently updating the format of select EasySep™ Mouse kits to include a Mouse FcR blocker instead of Normal Rat Serum. With this change, all components will now be shipped in a single package, while providing the same cell isolation performance as before.

EasySep™ Mouse B Cell Isolation Kit

15-Minute cell isolation kit using immunomagnetic negative selection

From: 771 USD
Catalog #
(Select a product)
15-Minute cell isolation kit using immunomagnetic negative selection
Add to Wish List

Product Advantages


  • Fast and easy-to-use

  • Up to 95% purity

  • No columns required

  • Untouched, viable cells

What's Included

  • EasySep™ Mouse B Cell Isolation Kit (Catalog #19854)
    • EasySep™ Mouse B Cell Isolation Cocktail, 0.5 mL
    • EasySep™ Streptavidin RapidSpheres™ 50001, 1 mL
    • EasySep™ FcR Mouse Blocker, 0.2 mL
  • RoboSep™ Mouse B Cell Isolation Kit (Catalog #19854RF)
    • EasySep™ Mouse B Cell Isolation Cocktail, 0.5 mL
    • EasySep™ Streptavidin RapidSpheres™ 50001, 1 mL
    • EasySep™ FcR Mouse Blocker, 0.2 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
Products for Your Protocol

Overview

The EasySep™ Mouse B Cell Isolation Kit is designed to isolate B cells from single-cell suspensions of splenocytes or other tissues by negative selection. Unwanted cells are targeted for removal with biotinylated antibodies directed against non-B cells and streptavidin-coated magnetic particles (RapidSpheres™ ). Labeled cells are separated using and EasySep™ magnet without the use of columns. Desired cells are poured off into a new tube.

For isolation of B cells expressing CD11b or CD43, we recommend using the EasySep™ Mouse Pan-B Cell Isolation kit (Catalog #19844).

This product replaces the EasySep™ Mouse B Cell Enrichment Kit (Catalog #19754) for even faster cell isolations.
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyPlate™ EasySep™ Magnet (Catalog 18102)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
B Cells
Species
Mouse
Sample Source
Other, Spleen
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Typical EasySep™ Mouse B Cell Isolation Profile

Figure 1. Typical EasySep™ Mouse B Cell Isolation Profile

Starting with mouse splenocytes, the B cell content (CD19+CD3-) of the isolated fraction is 97.6 ± 1.7% (mean ± SD), using the purple EasySep™ Magnet.

EasySep™ Cell Isolation Protocol Lengths

Figure 2. EasySep™ Cell Isolation Protocol Lengths

Typical time taken (in minutes) to isolate cells using select EasySep™ kits.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
19854RF
Lot #
All
Language
English
Catalog #
19854
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
19854RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
19854RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
19854RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
19854RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
19854RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
19854
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
19854
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
19854
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
19854
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Frequently Asked Questions

Can EasySep™ Streptavidin RapidSpheres™ be used for either positive or negative selection?

Currently, EasySep™ Streptavidin RapidSphere™ kits are only available for negative selection and work by targeting and removing unwanted cells.

How does the separation work?

Streptavidin RapidSphere™ magnetic particles are crosslinked to unwanted cells using biotinylated antibodies. When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a new tube.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ Streptavidin RapidSphere™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Are cells isolated using EasySep™ RapidSphere™ products FACS-compatible?

Yes. Desired cells are unlabeled and ready to use in downstream applications, such as FACS analysis.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

Publications (30)

Role of nanoscale antigen organization on B-cell activation probed using DNA origami. R. Veneziano et al. Nature nanotechnology 2020 jun

Abstract

Vaccine efficacy can be increased by arraying immunogens in multivalent form on virus-like nanoparticles to enhance B-cell activation. However, the effects of antigen copy number, spacing and affinity, as well as the dimensionality and rigidity of scaffold presentation on B-cell activation remain poorly understood. Here, we display the clinical vaccine immunogen eOD-GT8, an engineered outer domain of the HIV-1 glycoprotein-120, on DNA origami nanoparticles to systematically interrogate the impact of these nanoscale parameters on B-cell activation in vitro. We find that B-cell signalling is maximized by as few as five antigens maximally spaced on the surface of a 40-nm viral-like nanoparticle. Increasing antigen spacing up to {\~{}}25-30 nm monotonically increases B-cell receptor activation. Moreover, scaffold rigidity is essential for robust B-cell triggering. These results reveal molecular vaccine design principles that may be used to drive functional B-cell responses.
Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. N. K. Mehta et al. Nature biomedical engineering 2020 jun

Abstract

The formulations of peptide-based antitumour vaccines being tested in clinical studies are generally associated with weak potency. Here, we show that pharmacokinetically tuning the responses of peptide vaccines by fusing the peptide epitopes to carrier proteins optimizes vaccine immunogenicity in mice. In particular, we show in immunized mice that the carrier protein transthyretin simultaneously optimizes three factors: efficient antigen uptake in draining lymphatics from the site of injection, protection of antigen payloads from proteolytic degradation and reduction of antigen presentation in uninflamed distal lymphoid organs. Optimizing these factors increases vaccine immunogenicity by up to 90-fold and maximizes the responses to viral antigens, tumour-associated antigens, oncofetal antigens and shared neoantigens. Protein-peptide epitope fusions represent a facile and generalizable strategy for enhancing the T-cell responses elicited by subunit vaccines.
Bioluminescence for in vivo detection of cell-type-specific inflammation in a mouse model of uveitis. S. John et al. Scientific reports 2020 jul

Abstract

This study reports the use of cell-type-specific in vivo bioluminescence to measure intraocular immune cell population dynamics during the course of inflammation in a mouse model of uveitis. Transgenic lines expressing luciferase in inflammatory cell subsets (myeloid cells, T cells, and B cells) were generated and ocular bioluminescence was measured serially for 35 days following uveitis induction. Ocular leukocyte populations were identified using flow cytometry and compared to the ocular bioluminescence profile. Acute inflammation is neutrophilic (75{\%} of ocular CD45 + cells) which is reflected by a significant increase in ocular bioluminescence in one myeloid reporter line on day 2. By day 7, the ocular T cell population increases to 50{\%} of CD45 + cells, leading to a significant increase in ocular bioluminescence in the T cell reporter line. While initially negligible ({\textless} 1{\%} of CD45 + cells), the ocular B cell population increases to {\textgreater} 4{\%} by day 35. This change is reflected by a significant increase in the ocular bioluminescence of the B cell reporter line starting on day 28. Our data demonstrates that cell-type-specific in vivo bioluminescence accurately detects changes in multiple intraocular immune cell populations over time in experimental uveitis. This assay could also be useful in other inflammatory disease models.
New format, same high quality! You may notice that your kit contents and packaging look slightly different from previous orders. We are currently updating the format of select EasySep™ Mouse kits to include a Mouse FcR blocker instead of Normal Rat Serum. With this change, all components will now be shipped in a single package, while providing the same cell isolation performance as before.